• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Prelude Therapeutics downgraded by Barclays with a new price target

    6/20/24 7:37:20 AM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRLD alert in real time by email
    Barclays downgraded Prelude Therapeutics from Equal Weight to Underweight and set a new price target of $3.00
    Get the next $PRLD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PRLD

    DatePrice TargetRatingAnalyst
    9/19/2024$5.00Neutral → Buy
    H.C. Wainwright
    6/20/2024$3.00Equal Weight → Underweight
    Barclays
    3/13/2024$7.00Mkt Outperform
    JMP Securities
    2/20/2024$5.00Buy → Neutral
    H.C. Wainwright
    12/19/2023$10.00 → $4.00Equal-Weight → Underweight
    Morgan Stanley
    11/21/2022$8.00 → $6.00Neutral → Underperform
    BofA Securities
    9/9/2022$19.00 → $11.00Overweight → Equal-Weight
    Morgan Stanley
    7/29/2022$9.00Buy
    Jefferies
    More analyst ratings

    $PRLD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Baker Bros. Advisors Lp

      4 - Prelude Therapeutics Inc (0001678660) (Issuer)

      6/13/25 4:45:31 PM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Scherer Paul C

      3 - Prelude Therapeutics Inc (0001678660) (Issuer)

      6/13/25 4:43:00 PM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Sandor Victor

      4 - Prelude Therapeutics Inc (0001678660) (Issuer)

      6/13/25 4:15:50 PM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRLD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

      WILMINGTON, Del., June 02, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (NASDAQ:PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in two upcoming healthcare conferences in June. Jefferies Global Healthcare Conference 2025:On Thursday, June 5, 2025, at 3:10 p.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude will participate in a fireside chat. Goldman Sachs 46th Annual Global Healthcare Conference:On Wednesday, June 11, 2025, at 9:20 a.m. ET, Kris, Vaddi, Ph.D., Chief Executive Officer of Prelude will participate in a fireside chat. Live webcasts of the fireside chats can be accessed on the Company's

      6/2/25 7:30:00 AM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

      PRT3789 monotherapy and combination with docetaxel escalation enrollment is complete and the Company plans to present updated results in the second half of 2025 Enrollment of the Phase 1 study of Prelude's once daily, oral SMARCA2 degrader, PRT7732 is advancing rapidly, and an initial data update is anticipated in the second half of 2025 Current cash runway into the second quarter of 2026 with $103.1 million in cash, cash equivalents, restricted cash and marketable securities as of March 31, 2025  WILMINGTON, Del., May 06, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD), a clinical-stage precision oncology company, today reported its financial results for

      5/6/25 4:05:00 PM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prelude Therapeutics to Participate in Citizens Life Sciences Conference

      WILMINGTON, Del., May 01, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (NASDAQ:PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Citizens Life Sciences Conference taking place in New York on May 7, 2025. On Wednesday, May 7, 2025, at 11:00 a.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude, Jane Huang, M.D., President and Chief Medical Officer, and Peggy Scherle, Ph.D., Chief Scientific Officer will participate in a fireside chat. A live webcast of the fireside chat can be accessed on the Company's website under Events and Presentations. The recording will be archived and available on the Compa

      5/1/25 7:30:00 AM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRLD
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13D/A filed by Prelude Therapeutics Incorporated

      SCHEDULE 13D/A - Prelude Therapeutics Inc (0001678660) (Subject)

      6/13/25 5:21:09 PM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prelude Therapeutics Incorporated filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

      8-K - Prelude Therapeutics Inc (0001678660) (Filer)

      6/13/25 4:10:27 PM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Prelude Therapeutics Incorporated

      SCHEDULE 13G/A - Prelude Therapeutics Inc (0001678660) (Subject)

      5/15/25 5:20:50 PM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRLD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Prelude Therapeutics upgraded by H.C. Wainwright with a new price target

      H.C. Wainwright upgraded Prelude Therapeutics from Neutral to Buy and set a new price target of $5.00

      9/19/24 7:51:24 AM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prelude Therapeutics downgraded by Barclays with a new price target

      Barclays downgraded Prelude Therapeutics from Equal Weight to Underweight and set a new price target of $3.00

      6/20/24 7:37:20 AM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities initiated coverage on Prelude Therapeutics with a new price target

      JMP Securities initiated coverage of Prelude Therapeutics with a rating of Mkt Outperform and set a new price target of $7.00

      3/13/24 7:41:41 AM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care